No - Uric 300

Quick links to important sections

No - Uric 300

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of No - Uric 300

No-Uric 300 is a prescription-only oral medication used for the long-term chronic management of conditions associated with elevated levels of uric acid in the blood, known as hyperuricemia. It is not effective for providing pain relief during an acute gout flare or attack.

Quick Facts Overview

Property Description
Active Ingredient Allopurinol
Pharmacological Class Xanthine Oxidase Inhibitor (XOI)
Strength 300 mg (Oral Tablet)
Common Use Prevention of recurrent gout and uric acid kidney stones
Status Prescription Only (Rx)

The active ingredient in No-Uric 300 is allopurinol. This substance is structurally similar to a natural chemical found in the body, allowing it to inhibit the enzyme xanthine oxidase. This mechanism reduces the overall production of uric acid, thereby lowering the concentration in the blood and urine.

The medication is clinically recognized as an effective urate-lowering therapy and is frequently used to help dissolve existing uric acid crystals and prevent the formation of new deposits in the joints and kidneys. It is essential that patients understand No-Uric 300 must be taken consistently every day, even when symptoms are not present, to maintain controlled uric acid levels and prevent future complications.

What side effects are possible with No - Uric 300?

Possible side effects and safety information

The safety profile of No-Uric 300 (allopurinol) is classified in official regulatory documents according to the frequency and body system affected. All documented adverse reactions are based on information from government health authorities.


Adverse Reaction Classification

Classification Example Adverse Reaction (as documented) System-Organ Class Involved
Common Skin rash, Initial acute gout flare Skin and Subcutaneous Tissue, Musculoskeletal
Uncommon Hypersensitivity reactions, Nausea, Vomiting Immune System, Gastrointestinal
Rare Stevens-Johnson Syndrome (SJS), Hepatitis Skin and Subcutaneous Tissue, Hepato-biliary

Serious Adverse Reactions and Safety Constraints

Official regulatory sources specifically document Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as rare but clinically significant risks. The risk of these severe reactions is documented as highest during the first few months of treatment.

Population-specific safety considerations are noted for individuals with renal impairment, who require particular attention. Patients of specific descent (e.g., Han Chinese) who possess the HLA-B^*5801 allele have an officially noted, substantially increased risk of SCARs. The medication is formally contraindicated in patients with a history of severe hypersensitivity to allopurinol.

Time-Related Patterns: An initial increase in acute gout attacks, often referred to as a paradoxical flare, is classified as a common occurrence at the beginning of therapy. Safety monitoring notes may include requirements for checking liver and renal function periodically.

Overdose and Emergency Response

The official regulatory documents on No-Uric 300 (allopurinol) overdose focus primarily on the risk of life-threatening systemic toxicity and the necessary immediate emergency actions. In cases of massive oral ingestion, documented manifestations may include nausea, vomiting, diarrhea, and dizziness.

The most severe complication is the development of a hypersensitivity syndrome, which may progress to serious reactions like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). These severe outcomes affect the renal and hepatic systems, having the potential to cause acute renal failure and irreversible hepatotoxicity.

Regulatory authorities explicitly mandate that treatment with No-Uric 300 must be discontinued immediately and permanently at the very first appearance of a skin rash or any other sign suggesting a hypersensitivity reaction. Immediate medical help must be sought when these signs appear or in the event of a suspected massive overdose.

Management of allopurinol overdose is strictly supportive, as no specific antidote is known. Allopurinol and its active metabolite are known to be dialyzable. Patients with impaired renal function are identified as being at an increased risk of developing these severe, potentially fatal hypersensitivity reactions, a consideration also applied to individuals carrying the *HLA-B58:01 allele**.

Therapeutic Uses of No - Uric 300

No-Uric 300 is commonly used to provide supportive symptomatic assistance and is relevant in contexts involving heightened systemic burden related to elevated uric acid. It is applied across domains where additional symptomatic support is needed.

This medication is commonly used to help with gout and certain other conditions associated with high uric acid levels. This includes managing the manifestations of gouty arthritis (acute and chronic), is considered relevant for easing the occurrence of uric acid kidney stones in susceptible patients, and addresses specific conditions that lead to very high uric acid concentrations.

Relief for Symptoms in Gout and Gouty Arthritis

This medicine is commonly used to help with conditions presenting with acute episodes and helps address symptom clusters that may become intense or disruptive, such as the joint pain, swelling, and inflammation associated with gout. It is applied in addressing symptoms related to inflammatory or irritative states. By playing a role in managing conditions related to elevated uric acid, it contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

“Offers symptomatic relief that helps patients cope more steadily with difficult episodes.”

Management of Uric Acid-Related Conditions

No-Uric 300 is also used in other settings where symptoms create noticeable physiological strain. It is applied in addressing conditions involving episodic or fluctuating manifestations, such as certain types of uric acid-related kidney stones. This is relevant in contexts involving heightened systemic burden, supports patients during episodes of heightened discomfort, and is helpful in situations requiring temporary assistance in symptom stabilization.

Quick Fact: Relief for Acute Joint Discomfort

Regulatory References

  1. MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Who can and cannot use No - Uric 300? (Official Regulatory Information)

This section outlines the population eligibility and restrictions for No - Uric 300 (allopurinol) based strictly on governmental regulatory documents.

Eligibility Status Restriction/Conditional Use
Populations Contraindicated (Must Not Use) History of severe allergic reaction or hypersensitivity to allopurinol.
Individuals known to carry the *HLA-B58:01 allele** (e.g., of Han Chinese, Thai, or Korean descent), unless benefits are determined to outweigh the risks.
Conditions Prohibited for Initiation Patients currently experiencing an acute gout attack (treatment must not be started until the attack has fully subsided).

Age and Organ Status Official Eligibility Rule
Adults (18+) Approved for standard uses (gout, hyperuricemia, recurrent kidney stones).
Pediatric Patients Use is rarely indicated except in cases of hyperuricemia secondary to cancer therapy or specific hereditary enzyme disorders (e.g., Lesch-Nyhan syndrome). Safety is not established for all other conditions.
Renal or Hepatic Impairment Use is conditional. Patients with kidney or liver problems require a reduced daily dosage (use with caution).
Pregnancy/Lactation Pregnancy: Should not be used unless considered essential. Lactation: Use is conditional and requires a careful benefit-risk assessment.

Official Eligibility Statements

  • The medicine is not recommended for treating asymptomatic hyperuricemia.
  • Patients with chronic renal impairment and concomitant diuretic use may be at an increased risk of severe hypersensitivity reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Allopurinol, the active ingredient in No - Uric 300, is a xanthine oxidase inhibitor, a characteristic that defines its key drug interactions. These interactions can significantly affect the body’s processing of other medicines and potentially increase the risk of serious side effects.

Cytotoxic and Immunosuppressive Agents

  • Mercaptopurine and Azathioprine are substrates for xanthine oxidase. Concomitant use with allopurinol inhibits their breakdown, leading to significantly elevated concentrations of the cytotoxic drugs in the body. This combination poses a serious risk of life-threatening bone marrow suppression (e.g., leukopenia, pancytopenia). To manage this interaction, the dose of mercaptopurine or azathioprine must be substantially reduced, typically to one-third or one-fourth of the usual dose.

Anticoagulants and Cardiovascular Drugs

  • Warfarin effects may be enhanced by allopurinol, potentially increasing bleeding risk. Close monitoring of coagulation parameters is required.
  • Co-administration with Thiazide Diuretics (e.g., hydrochlorothiazide) or ACE Inhibitors (e.g., captopril, enalapril) may increase the risk of hypersensitivity reactions, particularly in patients with kidney impairment. Use requires caution and close monitoring for signs of rash or allergic response.

Antibiotics

  • The concurrent use of Ampicillin or Amoxicillin with allopurinol is consistently associated with a higher incidence of skin rash.

Mechanism of Action

Targeted Blockade of Xanthine Oxidase

The core mechanism of No-Uric 300 (Allopurinol) involves the dual-stage, long-acting inhibition of the xanthine oxidase ( XO) enzyme. Allopurinol acts as a substrate, converting to its active metabolite, oxypurinol, which then binds tightly to the enzyme's active site. This engagement blocks the final steps in the purine catabolism pathway, halting the body's natural production of uric acid.


Sustained Reduction in Uric Acid Production

By blocking the XO enzyme, the mechanism generates a direct physiological consequence: a sustained decrease in the concentration of uric acid in the blood and urine (hypouricemia). The purine precursors—hypoxanthine and xanthine—are significantly more water-soluble than uric acid, allowing them to be more readily cleared by the kidneys. This systemic reduction of uric acid concentration establishes the physiological conditions required to influence the solubility and precipitation equilibrium of urate crystals in tissues.


Mechanistic Constraint: No Acute Anti-Inflammatory Action

It is a critical constraint of this mechanism that its action is confined to metabolic regulation. The inhibition of XO has no inherent anti-inflammatory or analgesic properties and does not interact with the molecular pathways (like prostaglandin synthesis or cytokine release) responsible for acute inflammation. Therefore, the mechanism lacks direct biological activity on the acute inflammatory cascade during an active inflammatory episode.

Dosage and Administration Information

Instruction Map: How to use No - Uric 300 — Administration Guidelines

No-Uric 300, which contains allopurinol, is administered as an oral tablet for chronic management, though an intravenous (IV) form exists for specific scenarios when oral therapy is not possible, such as certain cancer treatments.

The goal of use is achieved through a structured process involving low-dose initiation and gradual increase, with adjustments based on individual patient parameters.


Dosing Schedule and Frequency

Regimen Element Description
Initial Oral Dose 100 mg once daily. Lower starting doses (leq 50 mg) are used for patients with impaired kidney function.
Titration The dose is typically increased in increments (e.g., 100 mg weekly) until the target serum uric acid level is reached.
Maximum Dose The maximum recommended oral daily dose is 800 mg.
Frequency Logic Doses up to 300 mg are often taken once daily. Doses exceeding 300 mg daily should be administered in divided doses to improve gastrointestinal tolerability.

Administration Conditions and Special Rules

  • Timing: The oral tablet is generally better tolerated and should be taken after a meal.
  • Fluid Intake: Patients must maintain sufficient fluid intake (a daily urinary output of at least 2 liters) to promote diuresis, which is an important aspect of proper use.
  • Kidney Impairment: Dosing must be significantly reduced in patients with poor renal function. For example, a maximum dose of 100 mg daily, or longer dose intervals (e.g., every other day), may be required for severe impairment or patients on dialysis.
  • Initiation: Treatment should not be started during an acute gout flare.
  • Missed Dose: If a dose is missed, patients should not double the dose at the next scheduled time.

Recent Clinical Evidence

Research evidence / Overview of studies for No-Uric 300


Evidence for Chronic Management of Gout and Hyperuricemia

Research explored this area primarily through Randomized Controlled Trials (RCTs) involving adult patients with chronic gout. Studies monitored the level of uric acid in the blood (a key biomarker) and the frequency of gout flares. The trials and subsequent reviews of the evidence describe patterns related to a consistent shift in the biomarker, where study results indicated most participants met the predefined biomarker threshold. Studies also reported how symptoms evolved, describing patterns related to the frequency of acute gout flares over time compared to control groups.

Research on Uric Acid-Related Conditions and Study Gaps

Research was conducted in the context of preventing high uric acid levels following specific cancer chemotherapy protocols (Tumor Lysis Syndrome prophylaxis). These clinical trials monitored changes in uric acid levels and described patterns related to a rapid shift in the biomarker during the critical treatment phase. For chronic issues like recurrent uric acid kidney stones, evidence is derived largely from long-term observational settings and small trials. In this chronic context, certainty remains low due to the absence of large, definitive RCTs directly exploring stone recurrence.

Long-Term Data and Research Uncertainty

The research landscape includes studies that have evaluated specific groups, such as older adults and individuals with chronic kidney disease (CKD). These studies explored how No-Uric 300 was observed in relation to uric acid levels and measures of renal health. However, several aspects remain insufficiently studied. Long-term outcomes related to patient-reported discomfort and functional stability are not well characterized. Additionally, one key limitation is the inconsistent findings and heterogeneity across studies when comparing allopurinol to certain other urate-lowering agents.

Key Studies & References

  1. 2020 American College of Rheumatology Guideline for the Management of Gout
  2. Allopurinol - StatPearls [Internet] (NIH)

Frequently Asked Questions (FAQ)

Common questions about No - Uric 300 (FAQ)


Q: How quickly should I expect to see an improvement after starting No - Uric 300?

A: Studies indicate that you can expect to see a reduction in the levels of uric acid in your blood within 2 to 3 days after starting the medication. However, the full therapeutic effect, where the medication reaches its steady state to manage uric acid, typically requires consistent treatment for one week or more to achieve.


Q: Does No - Uric 300 completely cure the underlying condition, or just manage the symptoms?

A: According to official regulatory documents, No - Uric 300 is intended for the long-term chronic management of conditions associated with high uric acid, such as gout. It is designed to lower and maintain uric acid levels to prevent future attacks and crystal formation. The drug is primarily used as a long-term management tool rather than a curative treatment.


Q: Are there any long-term risks associated with taking No - Uric 300 for many years?

A: The drug label does not specify a maximum safe duration, as it is often prescribed for chronic management. However, long-term use generally requires periodic monitoring of key organ functions, particularly the liver and kidneys. The risk of serious skin reactions is documented as being highest during the first few months of treatment.


Q: What is the maximum duration someone can safely take No - Uric 300?

A: No - Uric 300 is prescribed for chronic management, meaning it is often prescribed for long-term use to maintain uric acid levels. Official product information does not define a maximum duration of use. The treatment duration is determined by the ongoing need to manage the underlying medical condition.


Q: Is it true that No - Uric 300 can sometimes cause a flare-up when you first start taking it?

A: Yes, official safety information indicates that an initial increase in acute gout attacks, often called a paradoxical flare-up, is a common occurrence when starting treatment. During an initial flare-up, the medication is generally continued, and other treatments may be temporarily used to help manage the acute symptoms.


Q: Can women who are planning to become pregnant take No - Uric 300?

A: Based on regulatory information, allopurinol may pose a risk of fetal harm. It is generally recommended that individuals planning pregnancy discuss their treatment and the potential risks with a healthcare provider, as the medication is typically discontinued before conception.


Q: Why is it important to stay well-hydrated while taking No - Uric 300?

A: Official dosage instructions emphasize the requirement for sufficient fluid intake. This is important to promote diuresis (increased urination), which helps to flush out the medication's breakdown products and prevents the formation of kidney stones.


Q: How long after stopping No - Uric 300 will the medication stay in my system?

A: The active substance in the body, oxypurinol, has a half-life of about 15 hours. If treatment is stopped, uric acid levels will gradually return to their pretreatment levels. This return to baseline is slow, often taking 7 to 10 days.


Q: Is No - Uric 300 similar to other medications used for the same purpose?

A: No - Uric 300 is a Xanthine Oxidase Inhibitor (XOI), which works by reducing the formation of uric acid in the body. This is a different class and mechanism of action than uricosuric agents, which work by increasing the amount of uric acid the kidneys remove.


Q: Is No - Uric 300 available over the counter or is it prescription-only?

A: Official labeling confirms that No - Uric 300 is designated as a prescription-only drug. It is a HUMAN PRESCRIPTION DRUG and requires a prescription from a licensed healthcare provider.


Q: Are generic versions of No - Uric 300 as effective as the brand name?

A: Generic versions of allopurinol are approved by regulatory bodies (like the FDA) through an Abbreviated New Drug Application. This approval requires them to be shown as bioequivalent, meaning they are considered therapeutically equivalent and are expected to have the same clinical effect.


Q: Can No - Uric 300 interfere with birth control pills?

A: The official product label does not specifically list an interaction with hormonal contraceptives. However, allopurinol can affect how the body processes many different drugs, so it is important for individuals using birth control pills to discuss all potential interactions with a healthcare provider.


Q: Can No - Uric 300 cause hair loss or skin issues?

A: While the drug is clearly linked to a risk of skin issues, including common rashes and rare but serious reactions (SJS/TEN), official regulatory databases do not commonly list hair loss as a documented adverse reaction for this medication.


Q: Are there any known interactions between No - Uric 300 and common herbal supplements?

A: Official regulatory documents primarily focus on known drug-to-drug interactions. They do not typically test interactions with herbal supplements in the same way. It is generally advised that patients consult with a healthcare provider regarding the use of any herbal remedies while taking this medication.


Q: Does No - Uric 300 affect sleep patterns?

A: Safety information indicates that this medication may cause some individuals to feel drowsy, dizzy, or less alert. The presence of these effects may require caution when performing activities that demand focus or alertness.


Q: How is No - Uric 300 different from other uric acid lowering drugs?

A: No - Uric 300 (Allopurinol) is classified as a xanthine oxidase inhibitor (XOI). This means it works by inhibiting the enzyme responsible for creating uric acid, thereby reducing its production. This action differs from uricosurics, which lower uric acid by increasing its excretion via the kidneys.


Q: Can No - Uric 300 be crushed or split if someone has trouble swallowing pills?

A: The official label specifies the tablet for oral administration but does not provide explicit instructions for crushing or splitting. To maintain the intended release and effectiveness, the tablet is typically swallowed whole. Consultation with a pharmacist is recommended before altering the tablet.


Q: What are the main risks if I stop taking No - Uric 300 abruptly?

A: Stopping the medication abruptly will not cause a physiological withdrawal syndrome. However, the main risk is that your body's uric acid levels will slowly begin to rise again. This increase in uric acid greatly raises the risk of recurrent gout attacks and flares.


Q: Are there any non-medical uses or benefits people claim for No - Uric 300?

A: Official drug labeling explicitly states that No - Uric 300 is not an innocuous drug and is not recommended for the treatment of hyperuricemia without symptoms. It is intended only for its approved medical indications to manage specific conditions.


Q: Is it better to take No - Uric 300 in the morning or at night?

A: The official product information states that the medication can be taken at any time of the day. The key is to take the dose consistently at the same time every day. It is generally better tolerated when taken after a meal.


Q: What are the long-term effects of No - Uric 300 on joints?

A: No - Uric 300 is indicated for the long-term management of gout. Its purpose is to lower uric acid levels and ultimately help dissolve existing urate crystals. Over time, this reduction in crystal deposition helps to prevent further joint damage and reduces the frequency of acute gout flares.


Q: Does No - Uric 300 have any impact on blood sugar levels?

A: While not a primary indication, clinical resources suggest that allopurinol may enhance the hypoglycemic effects of insulin or other blood sugar-lowering medications. Patients taking both medications may necessitate careful monitoring of blood glucose levels.


Q: How long does it take for No - Uric 300 to reach its maximum effect in the body?

A: To achieve the full therapeutic effect, such as stabilizing and maintaining the target serum urate level, consistent daily dosing of No - Uric 300 is typically required for one to three weeks.


Q: What happens if I accidentally take two tablets of No - Uric 300?

A: Acute overdose symptoms are primarily reported as nausea, vomiting, diarrhea, and dizziness. In the event of an accidental overdose, seeking assistance from emergency medical services or a poison control center immediately is the appropriate action.


Q: Are there any patient assistance programs available for No - Uric 300?

A: While not listed on the regulatory label, various pharmaceutical manufacturers and non-governmental foundations often offer Patient Assistance Programs (PAPs) or copay relief programs. Resources may be available for eligible individuals to help cover the medication costs.

How should No - Uric 300 be stored and disposed of?

How to Store and Dispose of No-Uric 300 (Allopurinol 300 mg)

The storage and disposal of Allopurinol 300 mg tablets are strictly defined by regulatory requirements to ensure product integrity and safety.

Storage and Handling Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep away from heat, moisture, and direct light. Do not store in a damp place, such as a bathroom.
Packaging Keep the medication in its original container, tightly closed.
Child Safety Must be kept out of the sight and reach of children. Always lock safety caps.

Disposal Instructions

Expired or unused tablets must not be disposed of by flushing them down the sink or toilet, or by discarding them in household trash. Disposal must prevent the product from entering wastewater and soil. The official instruction is to utilize a drug take-back program or follow the specific disposal guidance provided by a healthcare professional for unused medication.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of No - Uric 300 found in:

A-Z Index: